Abbott's CardioMEMS sensor will now be available to patients with chronic heart failure through the NHS, as per NICE's ...
Investors have seemingly homed in on flat sales in the Watchman and electrophysiology segments of Boston’s cardio portfolio, prompting a stock fall.
The trial’s endpoints focus on the procedural and clinical performance of the system for pulmonary embolism treatment, assessing right heart function. Credit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results